Biogen Expands Isis Partnership in $100 Million Drug Deal

Biogen Idec Inc., the maker of the multiple sclerosis pill Tecfidera, expanded its partnership with Isis Pharmaceuticals Inc. in a deal worth at least $100 million to develop drugs for neurological disorders.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.